Table 6.
Summary of All Outcomes.
| Studies | Trial Enrollment (Ctr, VC) | Positive Outcomes | Negative Outcomes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Measure | Outcome Types | Outcome Count | Enrollment | Measure | Outcome Types | Outcome Count | Enrollment | |||
| 1 | Shafaei et al. (2019) [39] | 252 (126,126) | Troponin, CK-MB | Myocardial injury | 1 | 252 | 0 | |||
| 2 | Ramos et al. (2017) [44] | 67 (41,26) |
VC, FRAP, GSH | Antioxidants | 1 | 67 | CK-MB, LVEF, Infarct size |
Myocardial injury, Cardiac contractility, Infarct size |
3 | 67 |
| 3 | Valls et al. (2016) [40] | 43 (21,22) |
LVEF, VC, FRAP, GSH, 8-isoprotane, TIMI |
Cardiac contractility Antioxidants ROS, Reperfusion |
4 | 43 | CK-MB, LVEF |
Myocardial injury, Cardiac contractility |
2 | 43 |
| 4 | Wang et al. (2014) [41] | 532 (267,265) | Troponin, CK-MB, 8-OHdG |
Myocardial injury, ROS |
2 | 532 | 0 | |||
| 5 | Basili et al. (2010–2011) a | 56 (28,28) |
TxB2, sNOX2-dp, LVEF, 8-OHdG, sCD40L, 8-oxo-PGF2a, cTFC, TIMI |
Inflammation, Cardiac contractility, ROS, ROS, Reperfusion |
6 | 56 | hs-crp, TNFa, Troponin, | Inflammation, Myocardial injury | 2 | 56 |
| 6 | Gasparetto et al. (2005) [33] | 98 (49,49) |
TLVV, TAS, ROS, sVCAM-1 |
Cardiac contractility, Antioxidant, ROS, Endothelial dysfunction |
4 | 98 | 0 | |||
| 7 | Guan et al. (1999) [29] | 21 (11,10) |
0 | 8-epi-PGF2a in urine | ROS | 1 | 21 | |||
| 8 | Tardif et al. (1997) [55] | 116 (62,54) | 0 | Coronary artery restenosis | Coronary artery restenosis | 1 | 116 | |||
| Total | 1185(605, 580) | 18 | 1048 | 9 | 303 | |||||
The positive outcomes denote those showing significantly improvement in association with administration of vitamin C. The negative outcomes denote the count of those types of outcomes which are not showing significant improvement due to administration of vitamin C. “a”: indicates that three articles were combined to represent one trial, they were Basili et al., 2010 [43], Pignatelli et al. 2011 [42] and Basili et al., 2011 [34].